Alnylam Pharmaceuticals (ALNY) Expected to Announce Quarterly Earnings on Thursday

Alnylam Pharmaceuticals (NASDAQ:ALNY) will likely be announcing its earnings results before the market opens on Thursday, February 13th. Analysts expect the company to announce earnings of ($0.62) per share and revenue of $580.62 million for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Alnylam Pharmaceuticals Trading Down 1.8 %

Shares of Alnylam Pharmaceuticals stock opened at $268.99 on Wednesday. The company has a 50-day moving average of $253.54 and a two-hundred day moving average of $262.97. Alnylam Pharmaceuticals has a 12-month low of $141.98 and a 12-month high of $304.39. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The stock has a market cap of $34.69 billion, a PE ratio of -102.67 and a beta of 0.35.

Wall Street Analyst Weigh In

ALNY has been the subject of several research reports. Raymond James lifted their price objective on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. Wolfe Research downgraded Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. HC Wainwright reissued a “buy” rating and issued a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, January 13th. Sanford C. Bernstein cut their target price on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. Finally, StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 9th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have issued a buy rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $298.61.

Insider Activity at Alnylam Pharmaceuticals

In related news, Director Phillip A. Sharp sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CMO Pushkal Garg sold 52,592 shares of the business’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the sale, the chief marketing officer now directly owns 11,989 shares of the company’s stock, valued at approximately $3,416,865. This trade represents a 81.44 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 73,964 shares of company stock worth $20,622,925. 1.50% of the stock is owned by company insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.